- Home
- RDIB vs ABOS Comparison
RDIB vs ABOS Comparison
Compare RDIB & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- ABOS
- Stock Information
- Founded
- RDIB 1937
- ABOS 1996
- Country
- RDIB United States
- ABOS United States
- Employees
- RDIB N/A
- ABOS N/A
- Industry
- RDIB Movies/Entertainment
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- RDIB Consumer Discretionary
- ABOS Health Care
- Exchange
- RDIB Nasdaq
- ABOS Nasdaq
- Market Cap
- RDIB 162.8M
- ABOS 171.8M
- IPO Year
- RDIB N/A
- ABOS 2021
- Fundamental
- Price
- RDIB $6.49
- ABOS $2.31
- Analyst Decision
- RDIB
- ABOS Strong Buy
- Analyst Count
- RDIB 0
- ABOS 4
- Target Price
- RDIB N/A
- ABOS $9.00
- AVG Volume (30 Days)
- RDIB 5.5K
- ABOS 213.7K
- Earning Date
- RDIB 12-03-2024
- ABOS 11-12-2024
- Dividend Yield
- RDIB N/A
- ABOS N/A
- EPS Growth
- RDIB N/A
- ABOS N/A
- EPS
- RDIB N/A
- ABOS N/A
- Revenue
- RDIB $197,270,000.00
- ABOS N/A
- Revenue This Year
- RDIB N/A
- ABOS N/A
- Revenue Next Year
- RDIB $13.64
- ABOS N/A
- P/E Ratio
- RDIB N/A
- ABOS N/A
- Revenue Growth
- RDIB N/A
- ABOS N/A
- 52 Week Low
- RDIB $5.96
- ABOS $2.08
- 52 Week High
- RDIB $21.34
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- RDIB 42.22
- ABOS 38.80
- Support Level
- RDIB $5.96
- ABOS $2.23
- Resistance Level
- RDIB $6.78
- ABOS $2.45
- Average True Range (ATR)
- RDIB 0.44
- ABOS 0.24
- MACD
- RDIB -0.01
- ABOS -0.09
- Stochastic Oscillator
- RDIB 24.44
- ABOS 7.08
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.